IONIS PHARMACEUTICALS INC (IONS) is a publicly traded company in the Unknown sector. Across all available filings, 27 corporate insiders have executed 1188 transactions totaling $219.8M, demonstrating a bearish sentiment with -$219.8M in net insider flow. The most recent transaction on Jan 30, 2026 involved a sale of 5,296 shares valued at $439.4K.
No significant insider buying has been recorded for IONS in the recent period.
No significant insider selling has been recorded for IONS in the recent period.
Based on recent SEC filings, insider sentiment for IONS is bearish with an Insider Alignment Score of 0/100 and a net flow of -$219.8M. Insiders are reducing their positions, though this can be driven by factors unrelated to company outlook.
Insider trading at IONIS PHARMACEUTICALS INC (IONS) refers to stock transactions made by corporate insiders—executives, directors, and beneficial owners holding more than 10% of the company's shares. These individuals have access to material non-public information and are required by law to report their trades to the SEC within two business days. Currently, 27 insiders are actively trading IONS stock, having executed 1188 transactions in the past 90 days. The most active insider is Stanley T. Crooke (Executive), who has made 176 transactions totaling $56.7M.
Get notified when executives and directors at IONS file new Form 4 transactions
Date | Insider | Title | Type | Shares | Price | Value | Flags |
|---|---|---|---|---|---|---|---|
| Jan 30, 2026 | Baroldi Joseph | EVP, Chief Business Officer | Sale | 5,296 | $82.96 | $439.4K | |
| Jan 30, 2026 | Frank Bennett C. | EVP, Chief Scientific Officer | Sale | 5,885 | $82.95 | $488.1K | |
| Jan 30, 2026 | Birchler Brian | EVP, Corp and Development Ops | Sale | 6,179 | $83.03 | $513.0K | Large |
| Jan 30, 2026 | L. Hougen Elizabeth | EVP, Finance & CFO | Sale | 6,988 | $83.24 | $581.7K | C-SuiteLarge |
| Jan 30, 2026 | P. Monia Brett | Executive | Sale | 62,970 | $82.72 | $5.2M | Large |
| Jan 30, 2026 | R. O'neil Patrick | EVP CLO & General Counsel | Sale | 6,179 | $83.53 | $516.2K | Large |
| Jan 30, 2026 | Schneider Eugene | EVP, Chf Clinical Develop Ofcr | Sale | 6,179 | $83.45 | $515.6K | Large |
| Jan 30, 2026 | Swayze Eric | EVP Research | Sale | 6,179 | $82.93 | $512.4K | Large |
| Jan 29, 2026 | Baroldi Joseph | EVP, Chief Business Officer | Award | 10,278 | $N/A | $0 | |
| Jan 29, 2026 | Frank Bennett C. | EVP, Chief Scientific Officer | Award | 11,421 | $N/A | $0 | |
| Jan 29, 2026 | Birchler Brian | EVP, Corp and Development Ops | Award | 11,991 | $N/A | $0 | |
| Jan 29, 2026 | L. Hougen Elizabeth | EVP, Finance & CFO | Award | 13,562 | $N/A | $0 | C-Suite |
| Jan 29, 2026 | P. Monia Brett | Executive | Award | 122,214 | $N/A | $0 | |
| Jan 29, 2026 | R. O'neil Patrick | EVP CLO & General Counsel | Award | 11,991 | $N/A | $0 | |
| Jan 29, 2026 | Schneider Eugene | EVP, Chf Clinical Develop Ofcr | Award | 11,991 | $N/A | $0 |
| TYPE | COUNT | VALUE | % |
|---|---|---|---|
Sale(S) | 483 | $219.8M | 65.2% |
Exercise(M) | 528 | $101.6M | 30.1% |
Payment(F) | 47 | $14.9M | 4.4% |
Other(J) | 88 | $776.1K | 0.2% |
Award(A) | 38 | $0 | 0.0% |
Gift(G) | 4 | $0 | 0.0% |
Insider selling pressure at IONIS PHARMACEUTICALS INC has increased, with 27 insiders executing 1188 transactions across all time. Total sales of $219.8M significantly outpace purchases of $0, resulting in a net outflow of $219.8M. This selling activity appears largely discretionary, which may warrant closer attention from investors.